L-carnosine supplementation attenuated fasting glucose, triglycerides, advanced glycation end products, and tumor necrosis factor-alpha levels in patients with type 2 diabetes: a double-blind placebo-controlled randomized clinical trial
Houjeghani S, Kheirouri S, Faraji E, Jafarabadi MA
Published in Nutrition Research
Key Findings
L-carnosine 1 g/d for 12 weeks significantly lowered fasting glucose, triglycerides, serum advanced glycation end products and TNF-alpha versus placebo in type 2 diabetes.
Conclusions
Carnosine supplementation reduced circulating AGEs and related metabolic markers.
Limitations
Single-centre trial, 12-week duration, surrogate endpoints only.
Supplements Studied
l-Carnosine supplementation attenuated fasting glucose, triglycerides, advanced glycation end products, and tumor necrosis factor-alpha levels in patients with type 2 diabetes
Outcomes Measured
l-Carnosine supplementation attenuated fasting glucose, triglycerides, advanced glycation end products, and tumor necrosis factor-alpha levels in patients with type 2 diabetes
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.